Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.43 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093901 | 0.93 | MMP9 (0.46) | RAB9AMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL3102970 | 0.93 | MMP9 (0.46) | RAB9AMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL3092998 | 0.92 | NPC1 (0.51) | RAB9AENPP1MEN1KMT2AMAPT | |
| SCHEMBL3090792 | 0.92 | NPC1 (0.51) | RAB9AENPP1MEN1KMT2AMAPT | |
| SCHEMBL3085893 | 0.92 | NPC1 (0.52) | RAB9AENPP3ENPP1MEN1KMT2A | |
| SCHEMBL3096373 | 0.92 | NPC1 (0.52) | RAB9AENPP3ENPP1MEN1KMT2A | |
| SCHEMBL3090974 | 0.92 | MEN1 (0.50) | RAB9AENPP3ENPP1MEN1KMT2A | |
| SCHEMBL3093732 | 0.92 | LARS1 (0.44) | RAB9AMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL15000123 | 0.91 | LARS1 (0.49) | MEN1KMT2ALARS1 | |
| SCHEMBL3100199 | 0.91 | NPC1 (0.53) | RAB9AMEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | RAB9A 826/4885ENPP3 1838/4885ENPP1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.